Santhera Other Current Assets from 2010 to 2026
| SANN Stock | CHF 12.64 0.30 2.32% |
Other Current Assets | First Reported 2006-12-31 | Previous Quarter 3.5 M | Current Value 3.2 M | Quarterly Volatility 1.7 M |
Check Santhera Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Santhera Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.9 M, Interest Expense of 24.4 M or Selling General Administrative of 12.1 M, as well as many indicators such as Price To Sales Ratio of 4.39, Dividend Yield of 0.0 or PTB Ratio of 3.78. Santhera financial statements analysis is a perfect complement when working with Santhera Pharmaceuticals Valuation or Volatility modules.
Santhera | Other Current Assets |
The evolution of Other Current Assets for Santhera Pharmaceuticals Holding provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Santhera Pharmaceuticals compares to historical norms and industry peers.
Latest Santhera Pharmaceuticals' Other Current Assets Growth Pattern
Below is the plot of the Other Current Assets of Santhera Pharmaceuticals Holding over the last few years. It is assets expected to be converted into cash, sold, or consumed either in one year or in the operating cycle, which are not included under standard current asset categories. Santhera Pharmaceuticals' Other Current Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Santhera Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Other Current Assets | 10 Years Trend |
|
Other Current Assets |
| Timeline |
Santhera Other Current Assets Regression Statistics
| Arithmetic Mean | 2,120,275 | |
| Geometric Mean | 1,540,092 | |
| Coefficient Of Variation | 78.38 | |
| Mean Deviation | 1,282,644 | |
| Median | 2,036,000 | |
| Standard Deviation | 1,661,909 | |
| Sample Variance | 2.8T | |
| Range | 6M | |
| R-Value | 0.54 | |
| Mean Square Error | 2.1T | |
| R-Squared | 0.30 | |
| Significance | 0.02 | |
| Slope | 178,870 | |
| Total Sum of Squares | 44.2T |
Santhera Other Current Assets History
About Santhera Pharmaceuticals Financial Statements
Santhera Pharmaceuticals investors use historical fundamental indicators, such as Santhera Pharmaceuticals' Other Current Assets, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Santhera Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Other Current Assets | 4 M | 4.2 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Santhera Stock Analysis
When running Santhera Pharmaceuticals' price analysis, check to measure Santhera Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Santhera Pharmaceuticals is operating at the current time. Most of Santhera Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Santhera Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Santhera Pharmaceuticals' price. Additionally, you may evaluate how the addition of Santhera Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.